THERAMETRICS HOLDING AG (SIX: TMX) RECOGNISES IMPROVED MARKET RECOGNITION AND SUPPORT OF ITS FULLY OWNED SUBSIDIARY, PIERREL RESEARCH INTERNATIONAL AG (PRINT), AND NOMINATION OF MS MAXIME STEVENS AS PRINT BOARD MEMBER

THERAMETRICS HOLDING AG (SIX: TMX) RECOGNISES IMPROVED MARKET RECOGNITION AND SUPPORT OF ITS FULLY OWNED SUBSIDIARY, PIERREL RESEARCH INTERNATIONAL AG (PRINT), AND NOMINATION OF MS MAXIME STEVENS AS PRINT BOARD MEMBER

Stans, Switzerland, December 9, 2013 - Ms Maxime Stevens joined PRINT as CBDO (Chief Business Development Officer) in April 2013, tasked with the responsibility of strategically restructuring and realigning THERAMetrics holding AG (Group), preparing the foundations for long-term growth, operational excellence and the expansion of new geographic opportunities. In July 2013 Ms Maxime Stevens became PRINT CEO.
 
PRINT announces this month the nomination of Ms Maxime Stevens as new member of the Board of Directors.
 
During the last eight months approximately € 10 million in new contracts and amendments have been awarded to the Group, with additional substantial new contracts expected to be signed still this year. This reflects the significant strides of improvement already achieved in the last few months by the Group as an entirety; and the measures of support and confidence rewarded by the Sponsors. Recent awards include those from Sponsors from newer geographical arenas for the Group, including Israel, where Maxime was presenting at LifeSciences Israel only few weeks ago.
 
Equally significant is the rapidly increasing pipeline of the Group, now exceeding € 35 million, much of this will be realised in 2014, thus bolstering both revenues and backlogs.
 
About THERAMetrics holding AG
THERAMetrics holding AG is a tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX) and located in Stans (Switzerland).
 
For further information please contact
THERAMetrics holding AG
Investor and External Relations
Tel.: +41 79 285 37 81
www.therametrics.com<http://www.therametrics.com>
 
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.